Triglyceride-glucose index (TyG) as a novel biomarker in the era of cardiometabolic medicine.
Ashot Avagimyan, Nana Pogosova, Federica Fogacci, Elena Aghajanova, Zinaida Djndoyan, Dimitrios Patoulias, Lorenzo Lo Sasso, Marco Bernardi, Andrea Faggiano, Noushin Mohammadifard, Danilo Neglia, Stefano Carugo, Arrigo Cicero, Manfredi Rizzo, Giuseppe Biondi-Zoccai, Raffaele De Caterina, Nizal Sarrafzadegan
Author Information
Ashot Avagimyan: Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran. Electronic address: dr.ashotavagimyan@gmail.com.
Nana Pogosova: Deputy Director of Research and Preventive Cardiology, National Medical Research Centre of Cardiology named after E. Chazov, Moscow, Russia; Head of Evidence-Based Medicine Department, Institute of Medicine, Peoples' Friendship University of Russia (RUDN), Moscow, Russia.
Federica Fogacci: Atherosclerosis and Metabolic Disorders Research Unit, University of Bologna, Bologna, Italy.
Elena Aghajanova: Head of Endocrinology Department, Head of Endocrinology Unit of Muratsan University Clinic, Yerevan State Medical University after M. Heratsi, Yerevan, Armenia.
Zinaida Djndoyan: Head of Internal Diseases Propaedeutics Department, Head of Internal Diseases Unit, Mikaelyan University Clinic, Yerevan State Medical University after M. Heratsi, Yerevan, Armenia.
Dimitrios Patoulias: Outpatient Department of Cardiometabolic Medicine, Second Department of Cardiology, General Hospital "Hippokration", Aristotle University of Thessaloniki, Thessaloniki, Greece.
Lorenzo Lo Sasso: Catholic University of the Sacred Heart, Rome, Italy.
Marco Bernardi: Department of Medical-Surgical Sciences and Biotechnologies, Sapienza University of Rome, Latina, Italy.
Andrea Faggiano: Department of Cardio-Thoracic-Vascular Area, Foundation IRCCS Cà Granda Ospedale Maggiore Policlinico, Milan, Italy; Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy.
Noushin Mohammadifard: Head of Nutrition Department, Cardiovascular Research Institute the WHO Collaborative Centre, Isfahan University of Medical Sciences, Isfahan, Iran.
Stefano Carugo: Department of Cardio-Thoracic-Vascular Area, Foundation IRCCS Cà Granda Ospedale Maggiore Policlinico, Milan, Italy; Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy.
Arrigo Cicero: Hypertension and Cardiovascular Risk Research Unit, Medical and Surgical Sciences Department, Alma Mater Studiorum University of Bologna, Bologna, Italy; Cardiovascular Medicine Unit, IRCCS Policlinico S. Orsola-Malpighi di Bologna, Bologna, Italy.
Manfredi Rizzo: Head of Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties, School of Medicine, University of Palermo, Italy; Mohammed Bin Rashid University of Medicine and Health Sciences (MBRU), Dubai, United Arab Emirates.
Giuseppe Biondi-Zoccai: Department of Medical-Surgical Sciences and Biotechnologies, Sapienza University of Rome, Latina, Italy; Maria Cecilia Hospital, GVM Care & Research, Cotignola, Italy.
Raffaele De Caterina: Head of Cardiology Department, University of Pisa, Pisa, Italy.
Nizal Sarrafzadegan: Director of Cardiovascular Research Institute WHO Collaboration Centre, Isfahan University of Medical Sciences, Isfahan, Iran; School of Population and Public Health, Faculty of Medicine, University of British Columbia, Vancouver, Canada.
In the period of increasing prevalence of metabolic disorders such as obesity and diabetes, healthcare professionals are facing significant challenges. Therefore, an accurate global assessment of insulin resistance is of utmost importance. Current medical research is focused on identifying an easily accessible and reproducible gold-standard surrogate marker for insulin resistance. Ideally, such a marker would enable healthcare providers to predict the risk of type 2 diabetes and cardiovascular diseases. The triglyceride-glucose index (TyG) is a promising marker for preventive cardiology and cardiometabolic medicine. This narrative review article aims to provide a comprehensive evaluation of the credibility of TyG as a surrogate marker of insulin resistance among patients at different stages across the cardiometabolic continuum. This assessment fully complies with evidence-based medicine and offers valuable insight into the clinical utility of TyG.
